RxDoctor Payments Data

Richard Palmer, MD

Family Medicine · San Antonio, TXNPI 1396742128

Payments from drug & device makers

$12,515in general payments, 2019–2025

Across 761 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$985
  • GSK$864
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$471
  • plus $4K from 51 others

What the payments were for

  • Food & beverage$12,44599%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,515 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$102,721
Medicare patients
192
Services billed
1,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$84,192
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$25,274
JardianceEmpagliflozin15$22,035
Tresiba Flextouch U-200Insulin Degludec20$16,467
MounjaroTirzepatide12$13,977
Synjardy XrEmpagliflozin/Metformin Hcl20$13,076
Tresiba Flextouch U-100Insulin Degludec15$7,646
Trazodone Hcl103$2,615
Atorvastatin Calcium312$2,146
SynthroidLevothyroxine Sodium16$1,965
Albuterol Sulfate HfaAlbuterol Sulfate80$1,932
Metformin Hcl146$1,571
Tamsulosin Hcl84$1,566
Losartan Potassium204$1,548
Metoprolol Succinate120$1,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,809$84,19262 claims
Boehringer IngelheimJardiance, Synjardy Xr$405$35,11135 claims
GSKTrelegy Ellipta$864$25,27427 claims
Lilly USA, LLCMounjaro$985$13,97712 claims
AbbVieSynthroid$1,850$1,96516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →